~~<i id='429580ADE7'><strike id='429580ADE7'><tt id='429580ADE7'><pre id='429580ADE7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

Wikipedia

author：explore 2025-09-29 09:29:45 - browse：66

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： UCLA team creates talking throat patch for voice disorders

leisure time

Wikipedia

leisure time

knowledge

focus

hotspot

Illustration:ChristineKao/STAT;Photos:GettyTheunsettlingrealityofH5N1birdflucirculatingindairycowher

WSS

Amid AI frenzy, a top HHS official's quest to create safeguards

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

RaDonda Vaught links Vanderbilt hospital issues to patient death

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

First U.S. drug developed to treat liver disease MASH is approved

explore

Wikipedia

leisure time

Cancer drug shortages should be causing more outrage

HIV vaccine remains elusive. Immunologists keep trying new ideas

Jerome Adams on the need for new antivirals for Covid

How many hemophilia patients actually want gene therapy?

Apple is now the first public company to be valued at $3 trillion

Helping hospitals and community health centers plan for resilience

Affirmative action in medical school literally saved lives

Readout Newsletter: CAR

Wildfire smoke exposes gaps in outdoor worker protections

It's time to retire 'poor historian' from clinicians' vocabularies

Wikipedia

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Helping hospitals and community health centers plan for resilience

It's time to retire 'poor historian' from clinicians' vocabularies

HHS secretary Becerra pressed on Change HealthCare cyberattack

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

leisure time

knowledge

focus

hotspot